*EMBARGOED All research presented at the 2021 ACG Annual Scientific Meeting and Postgraduate Course is strictly embargoed until Sunday, October 24, 2021, at 3:30 pm EDT.
Oral 69 Racial Minorities With Inflammatory Bowel Disease Are Under-Represented in Clinical Trial Participation
Author Insight from Jellyana Peraza, MD, Montefiore Medical Center
What’s new here and important for clinicians?
This is one of the first studies to look at clinical trial enrollment among racial and ethnic minority adults with IBD in the United States. Race and ethnicity were found to be underreported in such trials. Compared to IBD prevalence, the overall enrollment rates in IBD trials are low across all racial groups. Moreover, White individuals were more likely to be enrolled than Black, Native American, or Hispanic participants. The underrepresentation of racial and ethnic minority groups in IBD clinical trials can impact the generalizability of the results. Future research should focus on identifying and addressing the factors that contribute to such disparities.
What do patients need to know?
Clinical trials provide the data required to approve and use new medications to treat IBD. Our study found that Black, Native American, and Hispanic populations have lower participation in clinical trials than White. Underrepresentation of a subset of the population can limit the proper use of the therapies being tested. The racial and ethnic disparities in research participation found by our study are concerning and demand providers and patients’ attention. Collaboration among investigators, industry, and the community is required to break down barriers and enable broad access to trials for underrepresented populations.
Jellyana Peraza, MD, Montefiore Medical Center
jperaza [at] montefiore [dot] org
Media Interview Requests
To arrange an interview with any ACG experts or abstract authors, please contact Becky Abel of ACG via email at mediaonly [at] gi [dot] org.